Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Optogenetically Engineered Neurons Differentiated from Human SH-SY5Y Cells Survived and Expressed ChR2 in 3D Hydrogel

Lee S-Y. et al, (2022), Biomedicines, 10, 1534 - 1534

Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination.

Su W. et al, (2022), Nat Commun, 13

Deregulation of HLA-I in cancer and its central importance for immunotherapy.

Hazini A. et al, (2021), J Immunother Cancer, 9

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.

Wan PK-T. et al, (2021), Mol Ther, 29, 1668 - 1682

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.

Khalique H. et al, (2021), J Immunother Cancer, 9

Tackling HLA Deficiencies Head on with Oncolytic Viruses.

Fisher K. et al, (2021), Cancers (Basel), 13

Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response.

Baugh R. et al, (2020), Cancers (Basel), 12

Development of a novel mammalian display system for selection of antibodies against membrane proteins.

Robertson N. et al, (2020), J Biol Chem

A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).

O'Cathail SM. et al, (2020), Radiat Oncol, 15

A Complete "Self-Repressing" Adenovirus System Enables Efficient Manufacture of Adeno-Associated Viral Vectors without Contamination by Adenovirus or Small Drugs

Su W. et al, (2020), MOLECULAR THERAPY, 28, 240 - 240

Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion.

Yousaf I. et al, (2020), Cancers (Basel), 12

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.

Pokrovska TD. et al, (2020), Cancers (Basel), 12

Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.

Lynn GM. et al, (2020), Nat Biotechnol, 38, 320 - 332

The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy

Dyer A. et al, (2020), Cytokine and Growth Factor Reviews

Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation.

Taverner WK. et al, (2019), Mol Ther Oncolytics, 15, 117 - 130

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.

Scott EM. et al, (2019), J Immunother Cancer, 7

Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference.

Dyer A. et al, (2019), Cancer Gene Ther, 26, 59 - 73

Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.

Dyer A. et al, (2019), Cancer Res, 79, 331 - 345

An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.

Freedman JD. et al, (2018), Cancer Res, 78, 6852 - 6865

Optogenetic control of iPS cell-derived neurons in 2D and 3D culture systems using channelrhodopsin-2 expression driven by the synapsin-1 and calcium-calmodulin kinase II promoters.

Lee S-Y. et al, (2018), J Tissue Eng Regen Med

Load More

1
2
3
4
5
6
7
...
»